


# ADVESTRA: GBL ACQUIRES A MAJORITY STAKE IN SANOPTIS

*Posted on 21 April 2022*



**Categories:** [Capital Markets](#), [News](#)

**Tags:** [Advestra](#), [Alexander Fisch](#), [Alexander von Jeinsen](#), [Anna Capaul](#), [Beda Kaufmann](#), [Sanoptis Group](#), [Slider](#), [telemos capital](#)



**Groupe Bruxelles Lambert** (GBL) acquires a majority stake in **Sanoptis**, a network of ophthalmology clinics across Germany and Switzerland, from the private equity **Telemos Capital**. GBL is committing up to EUR 750 million in equity for this transaction with the aim to accelerate the company's growth in partnership with its management and doctors.

In this sense, as part of the transaction, the incumbent management will increase its stake in the company by way of a substantial reinvestment. GBL and management plan to continue together the impressive growth story of Sanoptis, both in existing markets as well as in new ones.

Founded in 2018, Sanoptis is an European ophthalmology services provider with over 250 facilities, serving both publicly and privately insured patients. With approximately EUR 300 million of revenue in 2021, the company has a unique business model; it targets active partnerships with leading

surgeons who remain shareholders in their clinics after joining the Sanoptis group.

Groupe Bruxelles Lambert (GBL) is an established investment holding company, with over sixty years of stock exchange listing, a net asset value of EUR 22.5 billion and a market capitalization of EUR 15.3 billion at the end of December 2021. This transaction marks GBL's second consecutive private investment in the healthcare sector in 2022. Healthcare is one of GBL's four focus investment sectors, along with consumer experience, technology and sustainability.

[Advestra](#) acts as Swiss legal counsel to GBL in this transaction. The team includes **Beda Kaufmann** (partner, pictured), **Alexander von Jeinsen**, **Anna Capaul** and **Alexander Fisch** (all corporate/m&a).